Clinical Trial Detail

NCT ID NCT02864381
Title GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gilead Sciences
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Nivolumab

Andecaliximab + Nivolumab

Age Groups: senior adult

No variant requirements are available.